Citi raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $575 from $550 and keeps a Buy rating on the shares. The firm upped the price target after adding povetacicept to the company’s model.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on VRTX:
- Vertex Pharmaceuticals Hold Rating: Key Factors and Challenges in the IgA Nephropathy Market
- Vertex Pharmaceuticals’ Strategic Acquisition and FDA Breakthrough Designation Boosts Buy Rating
- Morning Movers: CarMax slips following second quarter results
- Vertex Pharmaceuticals granted breakthrough therapy designation for povetacicept
- Vertex Pharmaceuticals completes enrollment in IA cohort of AMPLITUDE trial